Business
We structure our business with a focus on markets and customers.
Emergent BioSolutions Inc.: Revenue declined 28.8% to $743M from $1.044B. Net income turned positive at $52.6M from a $191M loss. Free cash flow grew 338% to $157M from $35.8M. Operating margin expanded 2389 bps to 13.47%. Emergent BioSolutions Inc.'s annual comparison also shows inventory grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 28.8% to $743M from $1.044BWatch
- Profitability — Net income turned positive at $52.6M from a $191M lossOK
- Cash flow — Free cash flow grew 338% to $157M from $35.8MOK
- Margins — Operating margin expanded 2389 bps to 13.47%OK
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 12 salesWatch
Where the revenue comes from
Fiscal 2025, as Emergent BioSolutions Inc. reports it. History and quarterly detail are in the app.
- MCM Products$456.7M
- Commercial Products$226.1M
Leadership changes
From Emergent BioSolutions Inc.'s own filings, the day they're filed.
- John D. Fowler Jr · appointmenteff. 2026-03-01
- Haywood Miller · CEO · departureeff. 2024-02-21
- Donald DeGolyer · directors · appointmenteff. 2023-10-01
Latest filings
- 8-K · Company announcement2026-09-01
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-06-29
- 10-Q · Quarterly report2026-05-01
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Emergent BioSolutions Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.